Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Shanghai Chest Hospital
Pfizer
Second Affiliated Hospital of Nanchang University
Eli Lilly and Company
Shanghai Pulmonary Hospital, Shanghai, China
Sun Yat-sen University
Ruijin Hospital
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Lebanese University
N.N. Petrov National Medical Research Center of Oncology